Last reviewed · How we verify
NCT06718205
Open-label, Single-arm, Multicenter Phase II Study of Nimotuzumab Injection Combined With Sintilimab and Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 trial testing Nimotuzumab in Esophageal Cancer in 112 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 112 |
| Start date | 8 March 2023 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Nimotuzumab — full drug profile →
- Sintilimab — full drug profile →
- Paclitaxel-albumin — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Adults 18 to 75, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
PFS
Time frame: about 2 years
the first progression disease or death (whichever occurs first) from any cause
Sponsor's own description
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab combined with sindilizumab and chemotherapy in first-line treatment of advanced or recurrent or metastatic esophageal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06718205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nimotuzumab
Trials testing the same drug.
- NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
- NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06718205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 2 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06718205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing